New brain scans could reveal hidden clues in rare nerve disease
NCT ID NCT07635030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses special brain scans (MRS) to measure two natural chemicals, GABA and glutathione, in people with Friedreich's Ataxia (FRDA). Researchers want to see if these chemicals can serve as reliable markers of the disease and how they change after taking the drug Omaveloxolone. About 60 participants, ages 8 to 16, will have up to three scans over at least six months. The goal is to better understand FRDA and improve future treatment monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRDA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can voice and hearing tests reveal hidden clues to Friedreich's ataxia progression?
- Can advanced heart scans predict the biggest killer in Friedreich's ataxia?
- Video games and AI join the fight against a rare movement disorder
- Can a single gene fix a fatal heart condition? a trial aims to find out
- Brain function in Friedreich's ataxia: new clues from genetic testing
- Pregnancy safety of friedreich ataxia drug under scrutiny